GRAIL GRAL
GRAIL Q2 FY26: revenue $44.7M, up 26%; diluted EPS −$2.56
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001628280-26-054307
Key figures from this report
These are the numbers GRAIL reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$44.7M+26% from $35.5M in Q2 FY2510-Q income statement, on EDGAR
- Net income−$110.2MAgainst −$114.0M in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS−$2.56Against −$3.18 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$55.6M−56% from $127.4M in Q2 FY2510-Q balance sheet, on EDGAR
- Cash from operations−$80.7MAgainst −$77.0M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.
- Veracyte VCYT public float $1.7B, Jun 30, 2025
- CareDx CDNA public float $1.0B, Jun 30, 2025
- Caris Life Sciences CAI public float $3.9B, Jun 30, 2025
- RadNet RDNT public float $4.1B, Jun 30, 2025
- Guardant Health GH public float $6.2B, Jun 30, 2025
